Implementation of New Duties of the Center for Supporting Development of Unapproved Drugs, etc.
March 26, 2020
General Incorporated Association, Development Support Center for Unapproved Drugs
Japan Pharmaceutical Manufacturers Association
The complexity of drug targets, the sophistication and diversification of science and technology, and the rising cost of research and development are making it increasingly difficult for pharmaceutical companies to create new drugs on their own. In the future, industry-academia collaboration with academia, bio-ventures, or other companies with advanced technologies and knowledge, and industry-industry collaboration among pharmaceutical companies in non-competitive areas are expected to play an increasingly important role in new drug R&D.
In light of these circumstances, the Center for Supporting Development of Unapproved Drugs, etc. (CDC) was approved at today's extraordinary Assembly,
- Planning and operational management of research and development projects conducted jointly by multiple pharmaceutical companies or industry-academia-government
- Management of databases, assets, intellectual property, etc.
The decision was made to add the following as new operations and to change its name to the "Research and Development Support Center for New Drugs and Unapproved Drugs".
As the first initiative for this new operation, the JPMA plans to manage the operation of the project proposed in the "JPMA Policy Proposal 2019" released by the Japan Pharmaceutical Manufacturers Association in January last year.
With the addition of the new duties, the corporation will contribute to the promotion of industry-led drug discovery innovation.
Reference] Examples of projects to be undertaken in FY2020
- Construction of integrated databases of disease-specific information
In collaboration with the National Center for Advanced Research and Translational Medicine (NC), the project will acquire disease-specific omics data from clinical specimens owned by NC and prospectively collected clinical specimens, and construct a database that can be analyzed by pharmaceutical companies and utilized in drug discovery research. - Development and sharing of new modalities
The project aims to build an ecosystem that leads to practical application of new modality technology seeds and drug targets from academia by evaluating and advising them from the perspective of companies, and supporting them with assets owned by companies.
Outline of the Research and Development Support Center for New Drugs and Unapproved Drugs
| Location | Nihonbashi Life Science Bldg.
Nihonbashi Life Science Bldg. 6F, 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan tel: 03-5204-2311 fax: 03-5204-2321 |
|---|---|
| Establishment | May 29, 2009 |
| Members | Member companies (73 member companies of Japan Pharmaceutical Manufacturers Association) as of April 1, 2019 |
| Board of Directors | Representative Director: Fumimaro Takahisa (Chairman, Japan Association for the Promotion of Community Healthcare)
Executive Director: Hiroshi Fukano (Former Director, SHIONOGI & CO., LTD.) Director: Mikio Yamazaki (Former President, Niigata Pharmaceutical University) Director: Kyumao Toyoshima (Former Research Advisor, RIKEN) Director: Katsuhiko Asano (Former President, Kirin Pharma Company, Limited) Kiyoshi KITAZAWA (Former Managing Director, TAKEDA PHARMACEUTICAL COMPANY LIMITED) Hiroaki Nakatani (Former Executive Director, Japan Pharmaceutical Manufacturers Association) Director: Ryoji Nagasaka (Managing Executive Officer, General Manager of Secretarial Department, DAIICHI SANKYO CO., LTD. and Chairperson of JPMA Industrial Policy Committee) (newly appointed) Director: Yoshiharu Hayashi (Executive Officer, General Manager, Drug Discovery Division, Mitsubishi Tanabe Pharma Corporation) (newly appointed) Director: Kiyoshi Ota (Former Executive Vice President, Sumitomo Pharmaceuticals Co.) Director: Takafumi Yoshino (Former Executive Officer, Sankyo Company, Limited) |
| Purpose | The Company will be responsible for the research, development and approval, etc. of unapproved drugs, unapproved applicable drugs, and other drugs that are deemed particularly necessary for medical treatment in Japan (hereinafter referred to as "unapproved drugs, etc."). The purpose of the Committee is to contribute to the improvement of the health and medical care of the public and patients through support for research and development, acquisition of approval, etc. of unapproved drugs (hereinafter referred to as "unapproved drugs, etc.") and research and development contributing to drug discovery conducted jointly by its members. |
| Business | (1) Provide professional support to development companies in the research, development, production, etc. of unapproved drugs, etc.
(2) Provide support for various operations related to the acquisition of approval by development companies, etc. (3) Provide financial assistance necessary for research, development, production, etc. of unapproved drugs, etc. (4) Management of the "FY2009 Fund for Unapproved Drugs and New Influenza Vaccines, etc. (5) Research and development contributing to drug discovery (new) (6) Collection and provision of samples and information that contribute to drug discovery (new) (7) Other activities necessary to achieve the objectives of the Organization. |
Inquiries should be addressed to
Japan Pharmaceutical Manufacturers Association
- Contact person
- Makoto Nakai River
- Phone
- 03-3241-0326 (main) 03-3241-0390 (direct)